467 related articles for article (PubMed ID: 33520579)
1. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
Singh SK; Upadhyay AK; Reddy MS
3 Biotech; 2021 Feb; 11(2):93. PubMed ID: 33520579
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
3. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
Udofia IA; Gbayo KO; Oloba-Whenu OA; Ogunbayo TB; Isanbor C
Netw Model Anal Health Inform Bioinform; 2021; 10(1):22. PubMed ID: 33786291
[TBL] [Abstract][Full Text] [Related]
4. The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Saudi J Biol Sci; 2021 Feb; 28(2):1426-1432. PubMed ID: 33281478
[TBL] [Abstract][Full Text] [Related]
5.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
6. Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp.
Murali M; Gowtham HG; Ansari MA; Alomary MN; Alghamdi S; Almehmadi M; Singh SB; Shilpa N; Aiyaz M; Kalegowda N; Ledesma AE; Amruthesh KN
Curr Pharm Des; 2022; 28(12):969-980. PubMed ID: 35796443
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach.
Gangadharan S; Ambrose JM; Rajajagadeesan A; Kullappan M; Patil S; Gandhamaneni SH; Veeraraghavan VP; Nakkella AK; Agarwal A; Jayaraman S; Surapaneni KM
J Infect Public Health; 2022 Nov; 15(11):1180-1191. PubMed ID: 36240528
[TBL] [Abstract][Full Text] [Related]
8. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
9. Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An
Akinlalu AO; Chamundi A; Yakumbur DT; Afolayan FID; Duru IA; Arowosegbe MA; Enejoh OA
Sci Afr; 2021 Sep; 13():e00845. PubMed ID: 34308004
[TBL] [Abstract][Full Text] [Related]
10. Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an
Mutlu O; Ugurel OM; Sariyer E; Ata O; Inci TG; Ugurel E; Kocer S; Turgut-Balik D
J Biomol Struct Dyn; 2022 Feb; 40(2):918-930. PubMed ID: 32933378
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
12. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.
Elghoneimy LK; Ismail MI; Boeckler FM; Azzazy HME; Ibrahim TM
Comput Biol Med; 2021 Jul; 134():104468. PubMed ID: 34015671
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling and structure-activity relationship of a natural derivative of
Ayipo YO; Ahmad I; Najib YS; Sheu SK; Patel H; Mordi MN
J Biomol Struct Dyn; 2023 Mar; 41(5):1959-1977. PubMed ID: 35037841
[TBL] [Abstract][Full Text] [Related]
14. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.
Rameshkumar MR; Indu P; Arunagirinathan N; Venkatadri B; El-Serehy HA; Ahmad A
Saudi J Biol Sci; 2021 Jan; 28(1):448-458. PubMed ID: 33110386
[TBL] [Abstract][Full Text] [Related]
15. Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.
Tiwari V
Int J Biol Macromol; 2021 Feb; 171():358-365. PubMed ID: 33421473
[TBL] [Abstract][Full Text] [Related]
16. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
17. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach.
Hasan M; Parvez MSA; Azim KF; Imran MAS; Raihan T; Gulshan A; Muhit S; Akhand RN; Ahmed SSU; Uddin MB
Biomed Pharmacother; 2021 Aug; 140():111742. PubMed ID: 34052565
[TBL] [Abstract][Full Text] [Related]
18. Lipopeptides against COVID-19 RNA-dependent RNA polymerase using molecular docking.
Xia B; Luo M; Pang L; Liu X; Yi Y
Biomed J; 2021 Dec; 44(6 Suppl 1):S15-S24. PubMed ID: 34871815
[TBL] [Abstract][Full Text] [Related]
19. Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses.
Elkarhat Z; Charoute H; Elkhattabi L; Barakat A; Rouba H
J Biomol Struct Dyn; 2022 Jan; 40(1):361-374. PubMed ID: 32873176
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
